Back to search results

Study on KATP Channel Loss in Type 2 Diabetes

This study is looking into how the loss of KATP channels (which help control insulin release) might lead to type 2 diabetes. Researchers want to understand why, in type 2 diabetes, the body's beta-cells (β-cells) in the pancreas eventually stop making enough insulin, even though they initially make too much. You might be able to join if you are between 18 and 65 years old and have either normal blood sugar levels (normoglycemic) and a healthy weight, or normal blood sugar levels and obesity. The study involves taking a single 10 mg dose of glipizide, a medication that helps the pancreas release insulin. The main goal is to measure how much insulin your body produces 90 minutes after taking glipizide. The study plans to enroll 40 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 40 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will ingest a single dose of 10 mg glipizide. Insulin secretion will be measured 90 minutes after taking the medication.
Compensation
Not stated in the trial record.
Follow-up
Insulin secretion is measured at 90 minutes after glipizide ingestion. Further follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06830096

Role of KATP Channel Loss in Type 2 Diabetes

Recruiting
NAAges 18–65InterventionalBasic science
Washington University School of Medicine
~40 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:10 mg glipizide ingestion

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Insulin secretion
Measured over 90 minutes after glipizide ingestion

Conditions

Obesity and Type 2 Diabetes

Explore related trials

ObesityType 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Missouri1

Who to contact

Kyle Timmons
[email protected]
314-273-1879
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Lean-normoglycemic group (n=10): BMI ≥18.5 and \<25.0 kg/m², fasting plasma glucose concentration \<95 mg/dl, 2-hr oral glucose tolerance test plasma glucose concentration ≤140-mg/dl, and hemoglobin A1C (HbA1C) ≤5.6%.
Obesity-normoglycemic group (n=10): BMI ≥30 and \<50 kg/m², fasting plasma glucose concentration \<95 mg/dl, 2-hr oral glucose tolerance test plasma glucose concentration ≤140 mg/dl, and hemoglobin A1C (HbA1C) ≤5.6%.
Obesity-impaired fasting glucose group (n=10): BMI ≥30 and \<50 kg/m², fasting plasma glucose concentration 100-125 mg/dl, and 2-hr oral glucose tolerance test plasma glucose concentration \<200 mg/dl.
Obesity-type 2 diabetes group (n=10): BMI ≥30 and \<50 kg/m²; HbA1C 6.5-9.5%, fasting plasma glucose ≥126 mg/dl, 2-hr oral glucose tolerance test plasma glucose concentration ≥200 mg/dl and/or medical history of T2DM and currently using anti-diabetic medications.

Exclusion

Diabetes therapy with insulin at \>0.5 units/kg/day.
Any change in diabetes medication in previous 3 months.
Unstable weight (\>2% change during the last 2 months before entering the study).
Evidence of significant organ system dysfunction or disease other than obesity and T2D.
Regular use of tobacco products.
Excessive consumption of alcohol (≥3 drinks/day for men and ≥2 drinks/day for women).
Use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid-lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study.
Anemia (Hemoglobin \<10.0 g/dL).
Pregnant or breastfeeding.
Unable or unwilling to follow the study protocol or for any reason the research team believes the volunteer is not an appropriate candidate for this study, including non-compliance with screening appointments or previous medical visits.

What this trial measures

  • Insulin secretion90 minutes after glipizide ingestion

    Insulin secreted by pancreas into plasma measured over 90 minutes after glipizide ingestion. Insulin secretion will be calculated using a stepwise insulin secretion rate function to fit plasma C-peptide concentrations to a two-compartment model of C-peptide kinetics using population-based C-peptide model parameters.